Voyager Therapeutics
VYGR
69 hedge funds and large institutions have $58.6M invested in Voyager Therapeutics in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 32 reducing their positions, and 17 closing their positions.
134% more call options, than puts
Call options by funds: $272K | Put options by funds: $116K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.51% less ownership
Funds ownership: 62.14% → 58.63% (-3.5%)
12% less funds holding
Funds holding: 78 → 69 (-9)
39% less capital invested
Capital invested by funds: $96.8M → $58.6M (-$38.2M)
47% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 17
50% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$1.45M |
| 2 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$715K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$341K |
| 4 |
FT
Fiduciary Trust
Boston,
Massachusetts
|
+$303K |
| 5 |
Belvedere Trading
Chicago,
Illinois
|
+$204K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.03M |
| 2 |
Millennium Management
New York
|
-$794K |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$687K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$472K |
| 5 |
JP Morgan Chase
New York
|
-$441K |
VYGR Hedge Fund Activity: Q3 2021 in Review
69 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q3 2021, worth a combined $58.6M — down 39% from $96.8M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of VYGR and 9 opened new positions — a net loss of 8 holders — while 32 trimmed existing stakes and 16 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $1.45M. The largest seller was Citadel Advisors, cutting an estimated $2.03M.
- 69 institutional investors held Voyager Therapeutics (VYGR) as of Q3 2021, down from 78 in Q2 2021.
- Funds reported $58.6M of Voyager Therapeutics stock for Q3 2021, down 39% quarter-over-quarter.
- 9 funds opened new Voyager Therapeutics positions in Q3 2021 and 17 closed out, a net change of -8 holders.
- The largest Voyager Therapeutics buyer in Q3 2021 was EcoR1 Capital, an estimated $1.45M added.
- The largest Voyager Therapeutics seller in Q3 2021 was Citadel Advisors, an estimated $2.03M sold.
Based on aggregated 13F filings for Q3 2021.